https://orcid.org/0000-0002-7708-7699
References
- Aartsma-Rus A, Krieg AM. 2017. FDA approves Eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen Saga. Nucleic Acid Ther. 27(1):1–3.
- Echevarría L, Malerba A, Arechavala-Gomeza V. 2021. Researcher's perceptions on publishing "negative" results and open access. Nucleic Acid Ther. 31(3):185–189.
- Eilers W, Denti MA. 2021. Delivery of antisense RNA therapeutics: turning negative results into a positive development. Nucleic Acid Ther. 31(3):183–184.
- Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Echevarría L, et al. 2021. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med. 13(4):e13243.
- [ICH]. 2009. Guideline on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2) [accessed 2022 Aug 1]. https://www.ich.org/page/multidisciplinary-guidelines.
- Kazmi F, Yerino P, McCoy C, Parkinson A, Buckley DB, Ogilvie BW. 2018. An assessment of the in vitro inhibition of cytochrome P450 enzymes, UDP-glucuronosyltransferases, and transporters by phosphodiester- or phosphorothioate-linked oligonucleotides. Drug Metab Dispos. 46(8):1066–1074.
- Ledford H. 2018. Gene-silencing drug approved – US government okays first RNA-interference drug – after a 20-year wait. Nature. 560(7718):291–292.
- Mukherjee P, Aksamitiene E, Alex A, Shi J, Bera K, Zhang C, Spillman DR, Marjanovic M, Fazio M, Seth PP, et al. 2022. Differential uptake of antisense oligonucleotides in mouse hepatocytes and macrophages revealed by simultaneous two-photon excited fluorescence and coherent Raman imaging. Nucleic Acid Ther. 32(3):163–176.
- [UKRI] UK Research and Innovation. 2022. UK research and innovation – funding opportunity – early ideas to improve the delivery of nucleic acid therapeutics [accessed August 1]. www.ukri.org/opportunity/early-ideas-to-improve-the-delivery-of-nucleic-acid-therapeutics/.
- US Food and Drug Administration (FDA). 2019. Approval of Givosiran [accessed August 1]. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-givosiran-acute-hepatic-porphyria.
- US Food and Drug Administration (FDA). 2021. Approval of Inclisiran [accessed August 1]. www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-therapy-lower-cholesterol-among-certain-high-risk-adults.
- Wood MJA, Talbot K, Bowerman M. 2017. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. Hum Mol Genet. 26(R2):R151–R159.